Candriam S.C.A. Biogen Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Biogen Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 212,457 shares of BIIB stock, worth $29.9 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

212,457

Previous 266,459 20.27%

Holding current value

$29.9 Million

Previous $61.8 Million 33.33%

% of portfolio

0.24%

Previous 0.38%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$189.07 - $236.8 $10.2 Million - $12.8 Million	-54,002 Reduced 20.27%	212,457 $41.2 Million
Q2 2024 Aug 05, 2024	SELL	$190.52 - $236.72 $111,073 - $138,007	-583 Reduced 0.22%	266,459 $61.8 Million
Q1 2024 May 03, 2024	BUY	$212.02 - $267.71 $17.3 Million - $21.9 Million	81,757 Added 44.12%	267,042 $57.6 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $10.8 Million - $13 Million	-48,674 Reduced 20.8%	185,285 $47.9 Million
Q3 2023 Nov 13, 2023	BUY	$253.3 - $285.89 $15,704 - $17,725	62 Added 0.03%	233,959 $60.1 Million
Q2 2023 Aug 08, 2023	SELL	$275.25 - $318.06 $17.8 Million - $20.6 Million	-64,848 Reduced 21.71%	233,897 $66.6 Million
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $239,113 - $272,460	932 Added 0.31%	298,745 $83.1 Million
Q4 2022 Feb 13, 2023	BUY	$252.44 - $306.72 $11.8 Million - $14.3 Million	46,654 Added 18.58%	297,813 $82.5 Million
Q3 2022 Nov 10, 2022	SELL	$194.69 - $268.46 $201,309 - $277,587	-1,034 Reduced 0.41%	251,159 $67.1 Million
Q2 2022 Aug 03, 2022	BUY	$187.54 - $223.02 $1.71 Million - $2.04 Million	9,133 Added 3.76%	252,193 $51.4 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $4.88 Million - $6.15 Million	25,183 Added 11.56%	243,060 $51.2 Million
Q4 2021 Feb 10, 2022	SELL	$223.92 - $287.77 $12.3 Million - $15.8 Million	-54,766 Reduced 20.09%	217,877 $52.3 Million
Q3 2021 Nov 09, 2021	SELL	$282.99 - $369.05 $678,327 - $884,612	-2,397 Reduced 0.87%	272,643 $77.2 Million
Q2 2021 Jul 20, 2021	SELL	$259.0 - $414.71 $30 Million - $48 Million	-115,830 Reduced 29.63%	275,040 $95.2 Million
Q4 2020 Jan 22, 2021	BUY	$236.26 - $355.63 $5.5 Million - $8.28 Million	23,281 Added 6.33%	390,870 $95.7 Million
Q3 2020 Oct 19, 2020	BUY	$264.77 - $305.71 $7.06 Million - $8.15 Million	26,670 Added 7.82%	367,589 $104 Million
Q2 2020 Jul 23, 2020	SELL	$258.66 - $342.55 $13.8 Million - $18.3 Million	-53,346 Reduced 13.53%	340,919 $91.2 Million
Q4 2019 Jan 21, 2020	SELL	$220.06 - $304.07 $9.75 Million - $13.5 Million	-44,324 Reduced 10.11%	394,265 $117,000
Q3 2019 Oct 21, 2019	SELL	$217.44 - $243.88 $40.5 Million - $45.4 Million	-186,131 Reduced 29.79%	438,589 $102,000
Q2 2019 Aug 01, 2019	SELL	$219.29 - $241.72 $6.53 Million - $7.2 Million	-29,775 Reduced 4.55%	624,720 $145 Million
Q1 2019 May 02, 2019	BUY	$216.71 - $338.96 $18.4 Million - $28.7 Million	84,754 Added 14.88%	654,495 $155 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $17.2 Million - $21.8 Million	61,805 Added 12.17%	569,741 $171 Million
Q3 2018 Nov 07, 2018	BUY	$293.51 - $383.83 $60.3 Million - $78.8 Million	205,294 Added 67.83%	507,936 $179 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $25.1 Million - $29.9 Million	97,482 Added 47.52%	302,642 $87.8 Million
Q1 2018 May 09, 2018	BUY	$260.13 - $367.91 $41.9 Million - $59.2 Million	161,000 Added 364.58%	205,160 $56.2 Million
Q4 2017 Feb 07, 2018	SELL	$307.64 - $344.58 $73.3 Million - $82.1 Million	-238,317 Reduced 84.37%	44,160 $14.1 Million
Q3 2017 Nov 03, 2017	BUY	$281.15 - $329.69 $79.4 Million - $93.1 Million	282,477	282,477 $88.4 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

126M

Call Options Held

1.12M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.2B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account